A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors

This proposed Phase I clinical trial of SON-DP is an FIH, open-label, Phase Ia/Ib dose escalation and expansion study to evaluate the safety, tolerability, PK, and PD of SON-DP in participants with relapsed/refractory/intolerant to standard of care therapies, for advanced/ metastatic solid tumors.

Trial Details

NCT ID
NCT05989724
Phase
PHASE1
Sponsor
Qurgen Inc.
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • SON-DP
Locations (sample)
  • Gilbert, Arizona, United States|33.35283,-111.78903
  • Detroit, Michigan, United States|42.33143,-83.04575
  • Huntersville, North Carolina, United States|35.41069,-80.84285
  • Oklahoma City, Oklahoma, United States|35.46756,-97.51643
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Signed written informed consent;
  • Male or female participants aged ≥ 18 years;
  • For Phase Ia: Participants with histologic diagnosis and confirmed solid tumor; For Phase Ib: Participants with one of the four tumor types: breast…
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at study entry and an estimated life expectancy of at least 3 months;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →